A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study

Erin L. Schenk, Sumithra J. Mandrekar, Grace K. Dy, Marie Christine Aubry, Angelina D. Tan, Shaker R. Dakhil, Bradley A. Sachs, Jorge J. Nieva, Erin Bertino, Christine Lee Hann, Steven E. Schild, Troy W. Wadsworth, Alex A. Adjei, Julian R. Molina

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study'. Together they form a unique fingerprint.

Medicine & Life Sciences